AstraZeneca
As of the edition of 20 October 2026, AstraZeneca runs 445 drugs, 97 of them marketed; it is on route A at 94 targets and on route B at 51 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 26 company names in this family.
- Medimmune Oncology Inc: renamed in 2008
- ZS Pharma, Inc.: acquired in 2015; successor AstraZeneca
- Alexion Europe SAS: acquired in 2021; successor AstraZeneca
- LogicBio Therapeutics, Inc: acquired in 2022; successor AstraZeneca
Drugs by status
| Status | Count |
|---|---|
| Marketed | 97 |
| Active | 102 |
| Went quiet | 130 |
| Stopped | 86 |
| Status not established | 30 |
| Total | 445 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Metformin | none listed | 4 |
| Lidocaine | none listed | 2 |
| Durvalumab | Ends 2031 (orphan exclusivity) | 1 |
| Propofol | none listed | 0 |
| Ropivacaine | none listed | 2 |
| Rosuvastatin | none listed | 3 |
| Dapagliflozin | Ends 2029 (patent) | 2 |
| Fulvestrant | none listed | 1 |
| Olaparib | Ends 2028 (patent) | 3 |
| Amoxicillin | none listed | 0 |
| Budesonide | Ends 2029 (exclusivity) | 5 |
| Omeprazole | none listed | 2 |
| Ticagrelor | none listed | 1 |
| Tamoxifen | none listed | 0 |
| Gefitinib | none listed | 0 |
| Esomeprazole | none listed | 2 |
| Anastrozole | none listed | 1 |
| Quetiapine | none listed | 4 |
| Osimertinib | Ends 2032 (patent) | 0 |
| Hydrochlorothiazide | none listed | 4 |
| Metronidazole | none listed | 0 |
| Tremelimumab | Ends 2034 (computed from the first US licence) | 1 |
| Clarithromycin | none listed | 0 |
| Exenatide | Ended 2025 (patent) | 1 |
| Propranolol | none listed | 4 |
A route B row is one company at one target. 72 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 94 targets, route B at 51 targets.
All 145 rows on route A or B
In the product145 company-target rows on route A or B; 142 are not shown here, and no score is.
See all 145 targets where AstraZeneca needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 557 trials led
- Lungs and airways: 400 trials led
- Immune system: 303 trials led